within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02C_AntinematodalAgents.P02CA01_Mebendazole;

model Mebendazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.02,
    Cl = 3.333333333333333e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Mebendazole</td></tr><tr><td>ATC code:</td><td>P02CA01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>200</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Mebendazole is a broad-spectrum anthelmintic drug used for the treatment of various helminthic infections such as ascariasis, hookworm, whipworm, and pinworm. It is listed as an essential medicine by the WHO and remains an approved and widely used medication for parasitic worm infections in both adults and children.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Ceballos, L, et al., &amp; Lanusse, CE (2018). Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers. <i>PLoS neglected tropical diseases</i> 12(1) e0005945–None. DOI:<a href=\"https://doi.org/10.1371/journal.pntd.0005945\">10.1371/journal.pntd.0005945</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29346367/\">https://pubmed.ncbi.nlm.nih.gov/29346367</a></p></li><li><p>Villaverde, C, et al., &amp; Prieto, JG (1992). Albendazole and mebendazole uptake by isolated enterocytes. <i>Developmental pharmacology and therapeutics</i> 19(1) 27–31. DOI:<a href=\"https://doi.org/10.1159/000457459\">10.1159/000457459</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1307343/\">https://pubmed.ncbi.nlm.nih.gov/1307343</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P02CA01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Mebendazole;
